Page 2,672«..1020..2,6712,6722,6732,674..2,6802,690..»

New research uses stem cells as possible treatment for arthritis

Posted: August 17, 2012 at 6:11 pm

CTVNews.ca Staff Published Friday, Aug. 17, 2012 8:36AM EDT

A Toronto research team hopes to make hip and knee replacements a thing of the past as it explores the growth of new human cartilage using stem cells.

With an estimated four million Canadians suffering from arthritis, and that number expected to grow to seven million by 2031, doctors are hoping to use the stem cells to treat the deterioration of cartilage in joints. Although hip and knee replacements are a great operation, they improve patients lives in terms of pain, quality and function, theyre not your own joint, Dr. Nizar Mahomed told CTVs Canada AM on Friday. They dont last forever and they bring risks and limitations.

Mahomed, an orthopedic surgeon at Torontos Western Hospital, said 45,000 hip and knee replacement surgeries are performed in Canada each year. Many of the surgeries are to treat the damage left by arthritis, which he said is caused by aging, obesity and injuries.

The incident of arthritis increases with age, so as our population ages the prevalence of arthritis is going to continue to increase.

Mahomed and his colleagues are one of the first research teams in the world that have been able to grow human cartilage.

The team is now embarking on the next stage of the study, which will see the new tissue used in animals.

If we actually make it work in animals then one day well be able to bring it back into patients, said Mahomed.

He added that stem cells hold much hope for medicine in the future as studies are looking at using the cells to regenerate cardiac tissue and in the treatment of nerve and spinal cord injuries.

Mahomed said he hopes within five to 10 years the new technology can be used in human patients while putting an end to joint replacement surgeries.

See the article here:
New research uses stem cells as possible treatment for arthritis

Posted in Stem Cells | Comments Off on New research uses stem cells as possible treatment for arthritis

Stem Cells as Blood Vessels=Heart Tx?

Posted: August 17, 2012 at 6:11 pm

Researchers at Kings College London have developed the first artificial functioning blood vessel outside of the body, according to a release from the college. The vessels are made from reprogrammed stem cells from human skin. The team also saw the cells develop into a blood vessel inside the body for the first time.

The hope is that this new technique will eventually lead to a treatment for patients with heart disease. The plan is that the reprogrammed cells would be injected into a leg or even directly into the heart to restore blood flow. Another possibility would be to graft one of the artificially developed vessels into the body as a replacement for blocked or damaged vessels. The research team also believes the newly created vessels could be used to prevent leg amputation in diabetic patients with poor circulation.

The study, which was published in the journal Proceedings of the National Academy of Sciences, reports that the reprogrammed vascular cells have no risk turning into tumors.

The release quotes Professor Qingbo Xu of the British Heart Foundation as saying, "This is very exciting research . . . If we can develop this approach as personalized treatments for patients with the condition, it will be a significant step forward."

The researchers cautioned that this is an early study and that more research needs to be done regarding how this approach will works in patients, but Dr Hlne Wilson, Research Advisor at the British Heart Foundation, said: "The discovery could help lead towards future therapies to repair hearts after they are damaged by a heart attack. As well as playing a part in a possible future regenerative treatment, these cells might also be used in drug screening to find new treatments to tackle inherited diseases."

The rest is here:
Stem Cells as Blood Vessels=Heart Tx?

Posted in Stem Cells | Comments Off on Stem Cells as Blood Vessels=Heart Tx?

Embryonic Stem Cells Survive Freezing

Posted: August 17, 2012 at 2:11 am

Even after 18 years of frozen storage, human embryos can still produce viable stem cells for drug screening and biomedical research.

By Hayley Dunning | August 16, 2012

Cryopreservation of embryos in fertility centers is common, and concerns over damage to the embryo during thawing were largely allayed by the birth of a healthy boy in 2010 from 20-year old cryopreserved embryo. Last week (August 10), researchers in Thailand reported in BioResearch Open Access that they successfully induced the growth of stem cells from a set of 17- and 18-year-old frozen embryos.

The embryos were thawed, then cultured to the blastocyst stage and co-cultured with human foreskin fibroblasts which acted as feeder cells to maintain the growth of embryonic stem cells. The team used the same method to induce stem cells to grow from fresh embryos for comparison, and in cells from both sources they found similar levels of pluripotency.

The importance of this study is that it identifies an alternative source for generating new embryonic stem lines, using embryos that have been in long-term storage, BioResearch Open Access Editor-in-Chief Jane Taylor told Asian News International.

By Cristina Luiggi

A postdoctoral research fellow at Emory University falsifies stem cell research data.

By Megan Scudellari

Human embryonic stem cells swiftly kill themselves in response to DNA damage.

By Edyta Zielinska

View original post here:
Embryonic Stem Cells Survive Freezing

Posted in Stem Cells | Comments Off on Embryonic Stem Cells Survive Freezing

What Your Neural Stem Cells Aren't Telling You

Posted: August 16, 2012 at 10:11 am

Neural stem cells (green) in the hippocampus huddle around a neuron (purple), listening for stray signals.

In 2000, a team of neuroscientists put an unusual idea to the test. Stress and depression, they knew, made neurons wither and die particularly in the hippocampus, a brain area crucial for memory. So the researchers put some stressed-out rats on an antidepressant regimen, hoping the mood boost might protect some of those hippocampal neurons. When they checked in a few weeks later, though, the team found that rats hippocampuses hadnt just survived intact; theyd grown whole new neurons bundles of them. But thats only the beginning of our tale.

By the time 2009 rolled around, another team of researchers was suggesting that human brains might get a similar hippocampal boost from antidepressants. The press announced the discovery with headlines like, Antidepressants Grow New Brain Cells although not everyone agreed with that conclusion. Still, whether the principle applied to humans or not, a far more basic question was begging to be answered: How, exactly, does a brain tell new cells to form?

Well, through synapses, of course, you might answer and thatd be a very reasonable guess. After all, synapses are how most neurons talk to each other: electrochemical information is squirted from a tiny tendril of one neuron into the tip of a tendril on another; and cells throughout most of the brain share essentially this same mechanism for passing signals along: The signals coming out of Neuron As synapses keep bugging Neuron B by stimulating its synapses, until finally Neuron B caves under peer pressure and bugs Neuron C with the signal and so on.

There are, however, two significant exceptions to this system.

The first exception was discovered a few years ago, as scientists got more and more curious about the role of neuroglia (also known as just glia), synapse-less cells that many had assumed were just there to serve as structural support for neurons. A 2008 study showed that glia help control cerebral blood flow, and research in 2010 demonstrated that some glia cells known as astrocytes actively listen for and respond to certain neurotransmitter messages. These so-called quiet cells are actually pretty loud talkers once you learn to tune in to their chatter.

The second exception to the synapse rule is even more mysterious in large part because its a brand-new discovery: As the journal Nature reports, a team led by Hongjun Song at the Johns Hopkins University School of Medicine have found that neural stem cells listen in on the stray chemical signals that leak from synapses.

You can imagine neural stem cells as being sort of neural embryos depending on the surrounding conditions, they can develop into neurons or into glia. And heres whats strange about the way these cells communicate: They respond not to any single synaptic signal, but to the overall chemical vibe of their environment to chronic feelings of stress, for instance. By way of response, they may morph into neurons or glia or even tell the brain to crank out some all-new cells.

Neural stem cells seem to be particularly interested in the chemical GABA (gamma-aminobutyric acid) a neurotransmitter thats known to be involved in inhibiting signals from other neurons. When scientists artificially block these stem cells GABA receptors from receiving messages, the cells wake up and start replicating but when those GABA signals are allowed to reach the receptors, the stem cells stay dormant.

In this case, Song explains, GABA communication keeps the brain stem cells in reserve, so if we dont need them, we dont use them up.

Continued here:
What Your Neural Stem Cells Aren't Telling You

Posted in Stem Cell Videos | Comments Off on What Your Neural Stem Cells Aren't Telling You

Woman who once advocated for more Hispanic bone marrow donors needs donation herself

Posted: August 16, 2012 at 10:11 am

Photo by Rachel Denny Clow, Corpus Christi Caller-Times

Rachel Denny Clow/Caller-Times file Cristina Rodriguez sits with her dogs Coby (left) and Flower at her home. Rodriguez's friends and family will have a recruitment event Saturday to find a bone marrow match for the 31-year-old former Zumba instructor, who has non-Hodkgin lymphoma.

CONTRIBUTED PHOTO Former Zumba instructor Cristina Rodriguez leads a flash mob at La Palmera mall in December 2010, a month before she stopped teaching because she developed a pain in her hip. She later was diagnosed with non-Hodgkin lymphoma.

Photo by Rachel Denny Clow, Corpus Christi Caller-Times

Rachel Denny Clow/Caller-Times file Cristina Rodriguez, who raised awareness about the importance for Hispanics to donate bone marrow and stem cells, now needs a donation herself.

CORPUS CHRISTI Cristina Rodriguez once counted herself among the lucky blood cancer patients who could survive on chemotherapy and stem cell treatments from their own bone marrow.

Buoyed by this blessing, she advocated for less fortunate Hispanics who needed transplants.

Now, the Corpus Christi woman who raised awareness about the importance for Hispanics to donate bone marrow and stem cells needs a donation herself.

It was an ironic twist of fate made worse by her understanding of the cold hard facts: Hispanics have a harder time finding matching donors than do other ethnicities.

"I knew the statistics and all that so I'm like, 'Oh great. I'm another statistic basically,' " she said.

Follow this link:
Woman who once advocated for more Hispanic bone marrow donors needs donation herself

Posted in Stem Cell Treatments | Comments Off on Woman who once advocated for more Hispanic bone marrow donors needs donation herself

NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

Posted: August 16, 2012 at 4:13 am

NEW YORK, Aug. 15, 2012 (GLOBE NEWSWIRE) -- Amorcyte, a company of NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast growing cell therapy market, today announced that it received on August 9, 2012 approval to continue its PreSERVE AMI Phase 2 clinical trial following its first interim data and safety review by the Data Safety Monitoring Board (DSMB). The PreSERVE trial is a Phase 2, randomized, placebo controlled, double-blind study expected to include 160 patients at more than 40 clinical sites. The trial's product candidate, AMR-001, is designed to prevent major adverse cardiac events following acute myocardial infarction (AMI). Patient enrollment for the PreSERVE trial began in January 2012 and the Company anticipates completing enrollment in 2013 with six months initial data readout near the end of 2013.

"We are pleased that, similar to our Phase 1 trial, the first external review of our Phase 2 trial data confirms that there are no safety signals that would preclude the trial from continuing as planned," said Andrew L. Pecora, M.D. FACP CPE, Chief Medical Officer of NeoStem. "The PreSERVE AMI study to date indicates that multiple National Study sites are capable of acquiring the necessary volume of bone marrow to create the AMR-001 product five to seven days after an AMI in a safe and practical manner, and once created the product can be delivered and administered without a safety signal."

NeoStem management believes that cell therapy is a disruptive technology in the $50 billion worldwide regenerative medicine market. Many key opinion leaders in the scientific, medical and investment communities consider AMR-001 to be best in class. Peak annual worldwide sales of AMR-001 for this indication could exceed $1 billion based upon a conservative market penetration of its qualified target patient population. AMR-001 is protected by two issued and multiple pending U.S. patents with corresponding patent coverage in selected markets around the world. The Amorcyte AMR-001 product development program also extends to congestive heart failure (CHF). The Company is preparing to launch its CHF Phase 1 clinical trials in early 2013. The worldwide CHF patient population is estimated to be four times larger than that of AMI.

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial in 2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward-looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property; (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Continued here:
NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

Posted in Cell Therapy | Comments Off on NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

What Your Neural Stem Cells Aren’t Telling You

Posted: August 15, 2012 at 6:12 pm

Neural stem cells (green) in the hippocampus huddle around a neuron (purple), listening for stray signals.

In 2000, a team of neuroscientists put an unusual idea to the test. Stress and depression, they knew, made neurons wither and die particularly in the hippocampus, a brain area crucial for memory. So the researchers put some stressed-out rats on an antidepressant regimen, hoping the mood boost might protect some of those hippocampal neurons. When they checked in a few weeks later, though, the team found that rats hippocampuses hadnt just survived intact; theyd grown whole new neurons bundles of them. But thats only the beginning of our tale.

By the time 2009 rolled around, another team of researchers was suggesting that human brains might get a similar hippocampal boost from antidepressants. The press announced the discovery with headlines like, Antidepressants Grow New Brain Cells although not everyone agreed with that conclusion. Still, whether the principle applied to humans or not, a far more basic question was begging to be answered: How, exactly, does a brain tell new cells to form?

Well, through synapses, of course, you might answer and thatd be a very reasonable guess. After all, synapses are how most neurons talk to each other: electrochemical information is squirted from a tiny tendril of one neuron into the tip of a tendril on another; and cells throughout most of the brain share essentially this same mechanism for passing signals along: The signals coming out of Neuron As synapses keep bugging Neuron B by stimulating its synapses, until finally Neuron B caves under peer pressure and bugs Neuron C with the signal and so on.

There are, however, two significant exceptions to this system.

The first exception was discovered a few years ago, as scientists got more and more curious about the role of neuroglia (also known as just glia), synapse-less cells that many had assumed were just there to serve as structural support for neurons. A 2008 study showed that glia help control cerebral blood flow, and research in 2010 demonstrated that some glia cells known as astrocytes actively listen for and respond to certain neurotransmitter messages. These so-called quiet cells are actually pretty loud talkers once you learn to tune in to their chatter.

The second exception to the synapse rule is even more mysterious in large part because its a brand-new discovery: As the journal Nature reports, a team led by Hongjun Song at the Johns Hopkins University School of Medicine have found that neural stem cells listen in on the stray chemical signals that leak from synapses.

You can imagine neural stem cells as being sort of neural embryos depending on the surrounding conditions, they can develop into neurons or into glia. And heres whats strange about the way these cells communicate: They respond not to any single synaptic signal, but to the overall chemical vibe of their environment to chronic feelings of stress, for instance. By way of response, they may morph into neurons or glia or even tell the brain to crank out some all-new cells.

Neural stem cells seem to be particularly interested in the chemical GABA (gamma-aminobutyric acid) a neurotransmitter thats known to be involved in inhibiting signals from other neurons. When scientists artificially block these stem cells GABA receptors from receiving messages, the cells wake up and start replicating but when those GABA signals are allowed to reach the receptors, the stem cells stay dormant.

In this case, Song explains, GABA communication keeps the brain stem cells in reserve, so if we dont need them, we dont use them up.

The rest is here:
What Your Neural Stem Cells Aren't Telling You

Posted in Stem Cells | Comments Off on What Your Neural Stem Cells Aren’t Telling You

NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

Posted: August 15, 2012 at 6:11 pm

NEW YORK, Aug. 15, 2012 (GLOBE NEWSWIRE) -- Amorcyte, a company of NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a rapidly emerging market leader in the fast growing cell therapy market, today announced that it received on August 9, 2012 approval to continue its PreSERVE AMI Phase 2 clinical trial following its first interim data and safety review by the Data Safety Monitoring Board (DSMB). The PreSERVE trial is a Phase 2, randomized, placebo controlled, double-blind study expected to include 160 patients at more than 40 clinical sites. The trial's product candidate, AMR-001, is designed to prevent major adverse cardiac events following acute myocardial infarction (AMI). Patient enrollment for the PreSERVE trial began in January 2012 and the Company anticipates completing enrollment in 2013 with six months initial data readout near the end of 2013.

"We are pleased that, similar to our Phase 1 trial, the first external review of our Phase 2 trial data confirms that there are no safety signals that would preclude the trial from continuing as planned," said Andrew L. Pecora, M.D. FACP CPE, Chief Medical Officer of NeoStem. "The PreSERVE AMI study to date indicates that multiple National Study sites are capable of acquiring the necessary volume of bone marrow to create the AMR-001 product five to seven days after an AMI in a safe and practical manner, and once created the product can be delivered and administered without a safety signal."

NeoStem management believes that cell therapy is a disruptive technology in the $50 billion worldwide regenerative medicine market. Many key opinion leaders in the scientific, medical and investment communities consider AMR-001 to be best in class. Peak annual worldwide sales of AMR-001 for this indication could exceed $1 billion based upon a conservative market penetration of its qualified target patient population. AMR-001 is protected by two issued and multiple pending U.S. patents with corresponding patent coverage in selected markets around the world. The Amorcyte AMR-001 product development program also extends to congestive heart failure (CHF). The Company is preparing to launch its CHF Phase 1 clinical trials in early 2013. The worldwide CHF patient population is estimated to be four times larger than that of AMI.

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial in 2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward-looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property; (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Read more here:
NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

Posted in Cell Therapy | Comments Off on NeoStem Reports Data Safety Monitoring Board Recommends Continuation of PreSERVE AMI Phase 2 Trial

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018 …

Posted: August 15, 2012 at 12:15 pm

ALBANY, New York, August 15, 2012 /PRNewswire/ --

A new market report has been published by Transparency Market Research (http://www.transparencymarketresearch.com) titled "Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)Market - Global Scenario, Trends, Size, Growth and Industry Analysis, 2011-2018." Globally, CTCs and CSCs Market is estimated to reach USD 7.9 billion by 2018. The study shows that in the overall CTCs and CSCs global market, the U.S. is expected to maintain its lead position in terms of revenue till 2018. The global market for cancer diagnostics based on Circulating Cancer Cells (CTCs) was estimated at USD 1.0 billion in 2011.

Browse the full report athttp://www.transparencymarketresearch.com/circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market.html

The rising prevalence of diseases like cancer and the reimbursement support by regulatory bodies in developed countries like United States and Europe are the major factors driving the growth of the CTCs and CSCs market. Though the currently used detection method lacks sensitivity or specificity to track all CTCs particularly the ones that have lost characteristic epithelial features, there is still good scope for pharmaceutical companies in the CTCs and CSCs field. The various sub-types of cancer may have their own classes and it creates an opportunity in the future.

Increase in cancer mortality rate in the past few years and an increase in number of cancer patients offers an opportunity for pharmaceutical companies to enter this sector. Every one person out of eight has the potential of getting affected by cancer and it is estimated that 12 to 37 lives can be saved daily with the help of CTCs and CSCs.

The major geographic markets for CTCs and CSCs are the U.S. and Europe. The U.S. accounted for more than 50% of the worldwide CTCs and CSC market in 2011.

Related & Recently Published Reports by Transparency Market Research

Prostate Cancer Market

Weight Loss Industry

Osteoporosis Market

Read more from the original source:
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018 ...

Posted in Stem Cell Videos | Comments Off on Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018 …

LifeCell gets 50,000 customers in stem cells banking

Posted: August 15, 2012 at 1:10 am

Chennai, Aug 14 (IBNS)

Stem cells derived from the umbilical cord are known to have the potential to treat over 75 serious medical conditions.

To enhance awareness, LifeCell partnered with model and actor Lisa Ray, who had undergone successful stem cell therapy for treatment of blood cancer.

Lisa continues to endorse the brand.

Whilst India is the worlds largest birthing country, the penetration of the stem cell storage has been a dismal 0.2pc compared to the global average which is between 5pc in the US to as high as 25pc in Singapore.

LifeCell said it believes that poor awareness rate and per capita income are the primary reasons for low penetration in the Indian market, yet is optimistic that India would soon reach the global benchmarks.

Mayur Abhaya, Managing Director and CEO said, When we launched our services in 2004 the medical fraternity was not even aware of the concept of stem cell banking. It was our responsibility to create awareness amongst both the doctors and the expectant parents about its enormous scope in the future."

The stem cell storage industry is growing at a rate of 30-40pc per year. More and more innovative services have been launched in the space of stem cell preservation such menstrual blood banking. (IBNS)

See the article here:
LifeCell gets 50,000 customers in stem cells banking

Posted in Stem Cell Videos | Comments Off on LifeCell gets 50,000 customers in stem cells banking

Page 2,672«..1020..2,6712,6722,6732,674..2,6802,690..»